Upadacitinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2066 publications

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: June 23, 2026

Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.

Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.

Journal: bioRxiv : the preprint server for biology

Published: June 22, 2026

Outcomes of Upadacitinib Use in Non-Infectious Uveitis: Novel Report of 12 Cases and Summary of Published Reports.

Outcomes of Upadacitinib Use in Non-Infectious Uveitis: Novel Report of 12 Cases and Summary of Published Reports.

Journal: Ocular immunology and inflammation

Published: June 18, 2026

Successful Dual Treatment of Crohn's Disease and Atopic Dermatitis with Upadacitinib: Two Case Reports.

Successful Dual Treatment of Crohn's Disease and Atopic Dermatitis with Upadacitinib: Two Case Reports.

Journal: Internal medicine (Tokyo, Japan)

Published: June 17, 2026

Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission?

Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission?

Journal: Alimentary pharmacology & therapeutics

Published: June 16, 2026

Upadacitinib as a Successful Sequential Therapy After Abrocitinib Failure in a Patient With Refractory Darier Disease.

Upadacitinib as a Successful Sequential Therapy After Abrocitinib Failure in a Patient With Refractory Darier Disease.

Journal: American journal of therapeutics

Published: June 15, 2026

Salvage Therapy With Upadacitinib for Tofacitinib-Refractory Scarring Alopecia in an Asian Patient: Role of JAK1 Selective Inhibition.

Salvage Therapy With Upadacitinib for Tofacitinib-Refractory Scarring Alopecia in an Asian Patient: Role of JAK1 Selective Inhibition.

Journal: American journal of therapeutics

Published: June 15, 2026

Real-world efficacy of oral upadacitinib for vitiligo and factors associated with treatment response: A retrospective study.

Real-world efficacy of oral upadacitinib for vitiligo and factors associated with treatment response: A retrospective study.

Journal: JAAD international

Published: June 15, 2026

Prompt recurrence of granuloma annulare upon Janus kinase inhibitor discontinuation.

Prompt recurrence of granuloma annulare upon Janus kinase inhibitor discontinuation.

Journal: JAAD case reports

Published: June 12, 2026

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis.

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis.

Journal: Journal of comparative effectiveness research

Published: June 09, 2026

Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.

Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: June 09, 2026

Successful treatment of dupilumab-induced rosacea with upadacitinib in a patient with atopic dermatitis.

Successful treatment of dupilumab-induced rosacea with upadacitinib in a patient with atopic dermatitis.

Journal: Acta dermatovenerologica Alpina, Pannonica, et Adriatica

Published: June 04, 2026

Showing 1-12 of 2,066

Last Updated: 06/30/2026